Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 37 - Drugs for immunological or allergic disorders
Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141)
12/1995
12/12/1995US5475100 An antibody having antigen binding activity and which has a heavy chain constant region into which has been inserted arganine-glycine-aspartic acid and serine amino acid sequence, giving antibody affinity for cells
12/12/1995US5475092 Deliver cytotoxic drugs to specific cell population in targeted fashion
12/12/1995US5475033 Anti-allergic pharmaceutical composition for ophthalmic topical administration
12/12/1995US5475004 Angiotensin II receptor antagonists for the treatment and prophylaxis of coronary heart disease
12/12/1995US5474988 Analgesics, antiinflammatory agents
12/12/1995US5474987 Methods of using low molecular weight heparins treatment of pathological processes
12/12/1995US5474771 Inhibits T cell activation of B cells ; binds to epitope
12/11/1995CA2151113A1 Imidazolinyl tachykinin receptor antagonists
12/07/1995WO1995032984A1 New lipid esters of nucleoside monophosphates and their use as immunosuppressive drugs
12/07/1995WO1995032983A1 Post exposure prevention of hiv
12/07/1995WO1995032972A1 [a]-ANNELATED PYRROLE DERIVATIVES AND PHARMACEUTICAL USE THEREOF
12/07/1995WO1995032971A1 [a]-ANNELATED PYRROLE DERIVATIVES AND PHARMACEUTICAL USES THEREOF
12/07/1995WO1995032970A1 (a)-ANNELATED PYRROLE DERIVATIVES AND PHARMACEUTICAL USE THEREOF
12/07/1995WO1995032948A1 Quinoline derivatives as tachykinin nk3 receptor antagonists
12/07/1995WO1995032945A1 Compositions and methods for treating mast-cell mediated conditions
12/07/1995WO1995032731A2 Immunogenic pharmaceuticals
12/07/1995WO1995032726A1 Cyclosporin containing composition and process for the preparation thereof
12/07/1995WO1995032724A1 Glial mitogenic factors, their preparation and use
12/07/1995WO1995032719A1 Use of oligonucleotide phosphorothioate for depleting complement and for reducing blood pressure
12/07/1995WO1995032627A1 Use of fas ligand to suppress lymphocyte-mediated immune responses
12/07/1995WO1995024485A3 Coordinate in vivo gene expression
12/07/1995DE4419315A1 New hetero- and oxo-pyrrolizine derivs.
12/07/1995DE4419247A1 New pyrrolizine keto-acid, keto-ester and carboxamide derivs.
12/07/1995DE4419246A1 New hetero-aryl substd. pyrrolizine derivs.
12/07/1995CA2191745A1 [a]-annelated pyrrole derivatives and pharmaceutical uses thereof
12/07/1995CA2191192A1 Use of oligonucleotide phosphorothioate for depleting complement and for reducing blood pressure
12/07/1995CA2191085A1 Glial mitogenic factors, their preparation and use
12/07/1995CA2190862A1 Post exposure prevention of hiv
12/06/1995EP0685476A1 Benzo(5,6)cycloheptapyridines, compositions and methods of use
12/06/1995EP0684944A1 Coupling product obtained from hystamine and an amino acid
12/06/1995EP0684829A1 Role of atp-ubiquitin-dependent proteolysis in mhc-1 restricted antigen presentation and inhibitors thereof
12/06/1995EP0588850B1 N-hydroxyurea derivatives which inhibit lipoxygenase
12/06/1995EP0544819B1 Indole derivatives which inhibit leukotriene biosynthesis
12/06/1995EP0445255B1 Treatment of conditions and disease
12/06/1995CN1030452C Preparation of novel 2-aminopyrimidinone derivatives
12/05/1995US5472978 Aromatic compounds, pharmaceutical compositions containing them and their use in therapy
12/05/1995US5472964 Diaryl 5,6-fused heterocyclic acids as leukotriene antagonists
12/05/1995US5472947 Application of 4-carbamoyl-1-β-D-ribofuranosyl imidazolium-5-olate to the treatment of multiple sclerosis
12/05/1995US5472939 Method of treating complement mediated disorders
12/05/1995US5472707 High dose ranolazine formulations
11/1995
11/30/1995WO1995032282A1 Interleukin-6 splice variant
11/30/1995WO1995032219A1 Protein or polypeptide, process for producing the same, and intermediate compound tehrefor
11/30/1995WO1995032218A1 Neurotensin antagonist peptides
11/30/1995WO1995032217A1 Peptide antagonist intermediates of neurotensin
11/30/1995WO1995032200A1 Oxathiolanes, method for their preparation and pharmaceutical compositions containing same
11/30/1995WO1995031991A2 Use of magnesium-based products for the treatment or prophylaxis of neoplastic and autoimmune diseases
11/30/1995WO1995031990A1 Copolymer-1 improvements in compositions of copolymers
11/30/1995WO1995031985A2 Pharmaceutical compositions comprising an opiate antagonist and calcium salts, their use for the treatment of endorphin-mediated pathologies
11/30/1995WO1995031984A1 Method and reagents for the treatment of rheumatoid arthritis
11/30/1995WO1995029239A3 Compounds and methods for the stimulation and enhancement of protective immune responses and il-12 production
11/30/1995DE4421391C1 Verwendung von Antikörpern gegen T-Zellen zur verlängerten Immunsuppression Use of antibodies against T-cells for prolonged immunosuppression
11/30/1995DE4416402A1 Food supplement for stimulating immune system
11/30/1995CA2188582A1 Method and reagents for the treatment of rheumatoid arthritis
11/30/1995CA2167930A1 Oxathiolanes, method for their preparation and pharmaceutical compositions containing same
11/29/1995EP0684257A1 Pseudopeptide derivatives of neurokinines, process for their preparation and pharmaceutical compositions comprising them
11/29/1995EP0684255A1 7-Glycosyloxybenzopyran derivative and antiallergic agent containing the derivative as active ingredient
11/29/1995EP0684240A1 Hydroxamic acid derivatives with tricyclic substitution
11/29/1995EP0684231A1 Pharmaceutical preparation for modulating immunological reactions and new derivatives of indols and quinoline
11/29/1995EP0683793A1 Vaccines and methods for preventing and treating fescue toxicosis in herbivores
11/29/1995EP0683784A1 7,42-bis (o-demethyl) rapamycin
11/29/1995EP0683783A1 Rapamycin derivative process for its preparation and its use
11/29/1995EP0535059B1 Dna sequence for a serine protease and associated items
11/29/1995EP0460076B1 Genetically engineered immunoglobulins
11/29/1995EP0359783B1 Treatment of autoimmune diseases by oral administration of autoantigens
11/28/1995US5470962 Oligosialyl-1,2-dialkyl-sn-glycerols and synthetic intermediates for their preparation
11/28/1995US5470882 Diphenylsulfide with urea and sulfonates
11/28/1995US5470871 Therapeutic compositions based on 1,2-dithiole-3-thione derivatives
11/28/1995US5470855 Certain heterocyclic thiazole derivatives and their therapeutic use
11/28/1995US5470837 Autoimmune disease
11/28/1995US5470702 HIV-2 transmembrane glycoprotein homodimer (gp 80)
11/28/1995US5470569 Genetic engineering
11/23/1995WO1995031565A1 Alphavirus expression vector
11/23/1995WO1995031538A1 Human dna topoisomerase i-alpha
11/23/1995WO1995031472A1 Chimeric mhc class i antigens for inducing allograft tolerance
11/23/1995WO1995031468A1 Macrophage migration inhibitory factor-3
11/23/1995WO1995031463A1 New antagonist compounds
11/23/1995WO1995031437A1 Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudormophs thereof
11/23/1995WO1995031215A1 VACCINE FOR $i(MORAXELLA CATARRHALIS)
11/23/1995WO1995031213A1 IFN-β LIQUID FORMULATIONS
11/23/1995WO1995031208A1 Method of immunomodulation by means of adoptive transfer of antigen-specific cytotoxic t-cells
11/23/1995WO1995031206A1 P75 tnf receptor promoters
11/23/1995WO1995031205A1 Sialic acid/fucose based medicaments
11/23/1995WO1995031197A1 Methods of use for peroxynitrite decomposition catalysts, pharmaceutical compositions therefor
11/23/1995WO1995029236A3 Lymphocyte activation antigens and antibodies thereto
11/23/1995WO1995028957A3 Methods for inducing t cell tolerance to a tissue or organ graft
11/23/1995CA2190576A1 Chimeric mhc class i antigens for inducing allograft tolerance
11/23/1995CA2190465A1 Ifn-.beta. liquid formulations
11/23/1995CA2189528A1 Methods of use for peroxynitrite decomposition catalysts, pharmaceutical compositions therefor
11/23/1995CA2188421A1 Alphavirus expression vector
11/22/1995EP0682528A1 A pharmaceutical preparation for topical administration of antigens and/or vaccines to mammals via a mucosal membrane
11/22/1995EP0682526A1 PULMONARY ADMINISTRATION OF sCR1 AND OTHER COMPLEMENT INHIBITORY PROTEINS
11/22/1995EP0682516A1 Therapeutic use of compounds having selective agonist-like activity on rxr retinoid receptors
11/22/1995CN1112122A Sulfated-glycolipid derivatives as cell adhesion inhibitors
11/21/1995US5468879 Disubstituted acetylenes bearing heterobicyclic groups and heteroaromatic or phenyl groups having retinoid like activity
11/21/1995US5468756 Antiinflammatory, antiallergen
11/21/1995US5468743 Antiallergens
11/16/1995WO1995030900A1 MODULATORS OF CYTOKINES OF THE TGF-β SUPERFAMILY AND METHODS FOR ASSAYING FOR SAME
11/16/1995WO1995030763A2 Retroviral vectors having a reduced recombination rate
11/16/1995WO1995030761A2 Methods of in vivo gene delivery
11/16/1995WO1995030750A2 Lag-3 protein soluble polypeptide fractions, method of production, therapeutic composition and anti-idiotype antibody
1 ... 1061 1062 1063 1064 1065 1066 1067 1068 1069 1070 1071 1072 1073 1074 1075 1076 1077 1078 1079 1080 1081 ... 1172